慢性髓细胞白血病患者妊娠管理的研究进展  

Research progress on pregnancy management in patients with chronic myeloid leukemia

作　　者：余艳玲 余涛[2] 张龑莉[3] 黎纬明[4] Yu Yanling;Yu Tao;Zhang Yanli;Li Weiming(Department of Oncology,Affiliated Renhe Hospital of China Three Gorges University,Yichang 443000,Hubei Province,China;China Three Gorges University Health Science Center,Yichang 443000,Hubei Province,China;Department of Hematology,Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University,Zhenzhou 450000,Henan Province,China;Department of Hematology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei Province,China)

机构地区：[1]三峡大学附属仁和医院肿瘤科,宜昌443000 [2]三峡大学医学部,宜昌443002 [3]河南省肿瘤医院血液科,郑州450000 [4]华中科技大学同济医学院附属协和医院血液科,武汉430000

出　　处：《国际输血及血液学杂志》2024年第1期83-89,共7页International Journal of Blood Transfusion and Hematology

摘　　要：第一代酪氨酸激酶抑制剂(TKI)伊马替尼的问世,使慢性髓细胞白血病(CML)从一种致命性疾病转变为可控性慢性疾病,CML患者的长期生存率显著提高。在长期疾病控制中,CML年轻患者通常存在生育需求。目前,CML患者妊娠期使用TKI的安全性及其对妊娠结局的影响,仍尚未完全明确。如何在CML患者自身或其配偶妊娠期进行合理治疗的同时,保证母胎的安全性,已成为一项重大挑战。笔者对TKI及其他药物对CML患者妊娠结局的影响,以及CML患者的妊娠管理方面的研究进展进行综述,旨在为提高CML患者生活质量、改善妊娠结局提供理论依据。The introduction of imatinib,a first-generation tyrosine kinase inhibitor(TKI),has transformed chronic myeloid leukemia(CML)from a fatal disease to a manageable chronic disease,which can markedly enhance the long-term survival rate of CML patients.However,young CML patients often face reproductive considerations during their prolonged disease control.The safety profile of TKI administration during pregnancy in CML patients,along with its impact on pregnancy outcomes,remains incompletely elucidated.Balancing the imperative of ensuring maternal and fetal safety with the judicious treatment of CML patients during their own or their partner′s pregnancy poses a significant challenge.This article endeavors to elucidate on the effects of TKI and other pharmacotherapies on pregnancy outcomes in CML patients,while also addressing the intricacies of pregnancy management,in order to furnish a theoretical framework for enhancing the life quality of CML individuals and optimizing pregnancy outcomes in this population.

关 键 词：白血病 髓系 慢性 BCR-ABL阳性 酪氨酸激酶抑制剂 怀孕 妊娠结局 停药 

分 类 号：R733.72[医药卫生—肿瘤] R714[医药卫生—临床医学]